Physician profile
Robert B Raybon
NPI 1235173964
$8,117.90
in general payments reported to CMS, 2019-2025
36 companies · $987 in 2025
The $987 reported for 2025 was more than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $972 · 2020: $793 · 2021: $1,443 · 2022: $890 · 2023: $1,417 · 2024: $1,616 · 2025: $987.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,804 · Travel and Lodging: $1,194 · Education: $1,000 · Gift: $22.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,803.56 |
| Travel and Lodging | $1,194.05 |
| Education | $1,000.00 |
| Gift | $22.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,623.80 | 2021-2025 | Da Vinci Surgical System |
| Medtronic, INC. | $875.58 | 2021-2025 | Altaviva, Interstim, Truclear |
| Acessa Health INC. | $772.55 | 2021 | |
| Medtronic USA, INC. | $603.62 | 2019-2020 | |
| Astellas Pharma US INC | $566.09 | 2019-2024 | Veozah |
| Hologic Sales and Service, LLC | $367.26 | 2019-2025 | Acessa Provu System, Myosure Tissue Removal Device, Fluent Fluid Management System |
| Medical Device Business Services, INC. | $325.00 | 2020 | |
| Coloplast Corp | $246.36 | 2019-2023 | Saffron |
| Abbvie INC. | $229.32 | 2019-2025 | |
| Covidien Lp | $194.93 | 2019-2020 | |
| Caldera Medical, INC | $135.05 | 2022 | |
| Boston Scientific Corporation | $109.19 | 2019-2025 | Axonics, Advantage System |
| Axonics, INC. | $104.03 | 2020-2023 | Bulkamid |
| Urovant Sciences INC | $102.33 | 2022 | |
| Sumitomo Pharma America, INC. | $88.64 | 2023-2025 | Gemtesa, Myfembree |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Channel Medsystems, INC. | $73.55 | 2022 | |
| Integra Lifesciences Corporation | $68.12 | 2022 | |
| Conmed Corporation | $66.83 | 2025 | Airseal |
| Aspira Women'S Health INC | $59.93 | 2022 | |
| Minerva Surgical, INC | $57.95 | 2019-2025 | |
| Olympus America INC. | $56.59 | 2019-2024 | Olympus |
| Mayne Pharma Commercial LLC | $48.57 | 2025 | |
| Pfizer INC. | $48.12 | 2020-2021 | |
| Allergan, INC. | $42.42 | 2020-2021 | |
| C. R. Bard, INC. & Subsidiaries | $28.48 | 2019 | |
| Zyla Life Sciences, INC. | $27.13 | 2020 | |
| Ethicon US, LLC | $26.84 | 2021 | |
| Meditrina | $26.60 | 2019-2023 | |
| Duchesnay USA Incorporated | $26.12 | 2019 | |
| Palette Life Sciences, INC. | $22.61 | 2022 | |
| Therapeuticsmd, INC. | $20.54 | 2019 | |
| Smith+Nephew, INC. | $18.53 | 2024 | Stravix |
| 180 Medical, INC. | $14.53 | 2019 | |
| Baxter Healthcare | $14.44 | 2024 | Perclot |
| Amag Pharmaceuticals, INC. | $13.16 | 2019 | |
| Coopersurgical, INC. | $13.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Raybon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.